Genetic and Phenotypic Profiling of Triptan Users in a Swedish Cluster Headache Cohort
Journal of Molecular Neuroscience · 18.04.2024 · 74 (2)
DOI: 10.1007/s12031-024-02219-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Neuroscience, online erschienen am 18.04.2024. Verfasst von Felicia Jennysdotter Olofsgård und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cluster Headache. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Region Stockholm (ALF project), Karolinska Institutet Research Funds, Hjärnfonden.
Abstract (Originalsprache)
Up to 25% of individuals who live with cluster headache (CH), an extremely painful primary headache disorder, do not adequately respond to the first-line treatment, triptans. Studies have indicated that genetic variants can play a role in treatment response. Likewise, differences in clinical characteristics can give clues to mechanisms underlying triptan non-response. Our aim was to investigate five genetic variants previously implicated in triptan response and their relation to triptan usage in our Swedish CH cohort and to investigate potential distinctions in clinical characteristics. 545 CH patients were screened for the genetic variants rs1024905, rs6724624, rs4795541, rs5443, and rs2651899 with a case control design based on triptan usage. Analysis of clinical characteristics was based on self-reported questionnaire data from 893 patients. One genetic variant, rs1024905, was significantly associated with triptan non-usage in CH ( Pc = 0.010). In addition, multi-allele effector analysis showed that individuals with a higher number of effector variants were less likely to use triptans ( P = 0.007). Analysis of clinical characteristics showed that triptan users were more likely to have alcohol as a trigger (57.4% vs 43.4%, P = 0.002), have autonomic symptoms (95.1% vs 88.1%, P = 0.002), and be current smokers (27.0% vs 21.9%, P = 0.033) compared to non-users. These results support the hypothesis that genetic variants can play a role in triptan usage in CH and that patients with a typical CH phenotype are more likely to use triptans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Neurology, Danderyd Hospital, Stockholm, Sweden.
- Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. andrea.carmine.belin@ki.se.
Förderung
- Region Stockholm (ALF project)
- Karolinska Institutet Research Funds
- Hjärnfonden
- Mellby Gård Foundation
- Karolinska Institute
Zitieren
APA
Jennysdotter Olofsgård, F., Ran, C., Qin, Y., Fourier, C., Waldenlind, E., Steinberg, A., Sjöstrand, C., & Belin, A. C. (2024). Genetic and Phenotypic Profiling of Triptan Users in a Swedish Cluster Headache Cohort. Journal of Molecular Neuroscience, 74(2). https://doi.org/10.1007/s12031-024-02219-1
Vancouver
Jennysdotter Olofsgård F, Ran C, Qin Y, Fourier C, Waldenlind E, Steinberg A, et al. Genetic and Phenotypic Profiling of Triptan Users in a Swedish Cluster Headache Cohort. Journal of Molecular Neuroscience. 2024;74(2). doi:10.1007/s12031-024-02219-1
BibTeX
@article{JennysdotterOlofsgrd2024,
author = {Jennysdotter Olofsgård, Felicia and Ran, Caroline and Qin, Yuyan and Fourier, Carmen and Waldenlind, Elisabet and Steinberg, Anna and Sjöstrand, Christina and Belin, Andrea Carmine},
title = {Genetic and Phenotypic Profiling of Triptan Users in a Swedish Cluster Headache Cohort},
journal = {Journal of Molecular Neuroscience},
year = {2024},
volume = {74},
number = {2},
doi = {10.1007/s12031-024-02219-1}
}
EUVIMED